Retention of clinical biosamples / blank matrices [Regulatives / Guidelines]

posted by Ohlbe – France, 2019-04-24 13:54 (2264 d 17:33 ago) – Posting: # 20219
Views: 3,785

Hi John,

❝ Do you know why some sponsors want to have their samples kept until application approved?


"Because we've always done it", I guess...

❝ From EMA or FDA, is there a requirement mentioned in any of the guidances?


EMA: no. FDA: not that I know of.

❝ We are doing this (store samples) as well and I wonder why we need to if the age of the samples exceeds the long term stability date.


I agree with ElMaestro: some sponsors just want to be on the safe side and only repeat the bioanalytical part rather than the whole study if the lab messed up somewhere. There was a time also when guidelines or requirements were not as clear as they can be now and an Agency would unexpectedly ask for the metabolite in addition to the parent, or similar stuff.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,676 registered users;
25 visitors (0 registered, 25 guests [including 15 identified bots]).
Forum time: 07:28 CEST (Europe/Vienna)

Many people tend to look at programming styles and languages like religions:
if you belong to one, you cannot belong to others.
But this analogy is another fallacy.    Niklaus Wirth

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5